MLAB
Mesa Laboratories, Inc.
MLAB has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over MLAB overall, supported by stronger fundamentals and stronger modeled upside.
MLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Healthy |
MLAB's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
MLAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $135 | — |
| Current | 118x | $135 | — |
| Cheap | 142x | $163 | +20% |
| Fair | 301x | $346 | +156% |
| Expensive | 570x | $656 | +385% |
Historical ranges are pointers, not guarantees.
MLAB's PE is in its cheap range at 118x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK has the edge over MLAB in the historical PE scenario, which offers more potential upside but is not a forecast.
MLAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLAB's earnings to grow and its profitability to improve, with its revenue holding steady.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over MLAB on the outlook, with more favorable revenue expectations.
MLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.01 | +858% |
| Q3 2026 | $1.15 | +$1.46 |
| Q2 2026 | $0.85 | +$0.98 |
| Q1 2026 | $1.21 | +$1.57 |
| Q4 2025 | $0.65 | +$46.97 |
| Q3 2025 | -$0.31 | +$45.31 |
| Q2 2025 | -$0.13 | +$46.35 |
| Q1 2025 | -$0.36 | +$46.84 |
| Q4 2024 | -$46.32 | -25833% |
MLAB has returned to profit: it earned $1.15 per share over the past year, after losing money the year before.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over MLAB in the latest year-over-year earnings comparison.
MLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | +2.6% |
| Q2 2026 | $60.1M | +1% |
| Q1 2026 | $63.7M | +2.6% |
| Q4 2025 | $65.1M | +3.6% |
| Q3 2025 | $60.7M | +5% |
| Q2 2025 | $59.5M | +2.4% |
| Q1 2025 | $62.1M | +5.5% |
| Q4 2024 | $62.8M | +18% |
MLAB's revenue has grown year over year for 11 quarters in a row: $62M last quarter, up 2.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +5.7 points |
| Q2 2026 | 12% | +6.5 points |
| Q1 2026 | 4.3% | +1.9 points |
| Q4 2025 | 12% | +3.1 points |
| Q3 2025 | 7.8% | +1.7 points |
| Q2 2025 | 5.2% | -4.4 points |
| Q1 2025 | 2.4% | +463 points |
| Q4 2024 | 9.2% | +9.3 points |
MLAB's operating margin was 13% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2019.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK's revenue has grown year over year for six quarters in a row: $11B last quarter, up 378% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over MLAB on profitability, with a higher operating margin.
MLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7M | -48% |
| Q2 2026 | $14.2M | +1504% |
| Q1 2026 | $13.5M | +14% |
| Q4 2025 | $18M | +2.2% |
| Q3 2025 | $7.1M | +105% |
| Q2 2025 | $884K | -91% |
| Q1 2025 | $11.9M | -3.6% |
| Q4 2024 | $17.6M | +69% |
MLAB generated $49M in free cash flow over the past year, up 32% from the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK generated $17.4B in free cash flow over the past year, more than ten times what it generated the year before.
MLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3K shares |
| 1 year | +4.1% | +225K shares |
| 3 years | +6.9% | +373K shares |
| 5 years | +7.8% | +416K shares |
| Available history | +32% | +1.4M shares |
MLAB has 6M diluted shares, up 4.1% from a year ago.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has the edge over MLAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
MLAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q3 2023 | -1.0x | Net Cash |
MLAB's net debt is about 1.4 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has the edge over MLAB on leverage, with a lower net debt burden relative to earnings.
MLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 72.9 | Neutral |
MLAB's weekly RSI is 65 (neutral) and its Stochastic is 73 (neutral).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
MLAB PE vs Technology Sector
| Metric | MLAB | Sector median | Relative |
|---|---|---|---|
| PE | 118x | 28x | 322% above |
| PE % | 12 | 35 | 23 pts below |
MLAB is trading at 118x earnings, a 322% premium to the Technology sector's median of 28x.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over MLAB on valuation relative to its sector.
MLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 4.4% above |
| 20 week MA | $118.6 | 14% above |
| 50 week MA | $102.2 | 32% above |
| 100 week MA | $101.9 | 33% above |
| 200 week MA | $112.8 | 20% above |
MLAB has stronger trend alignment. MLAB is above 5 of 5 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
MLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $247.3 | $284.8 | +15% |
| 2021 | $284.8 | $328.9 | +15% |
| 2022 | $328.9 | $162.8 | -50% |
| 2023 | $162.8 | $104.8 | -36% |
| 2024 | $104.8 | $133.1 | +27% |
| 2025 | $133.1 | $80.5 | -40% |
| 2026 YTD | $80.5 | $135.2 | +68% |
MLAB is up 68% so far in 2026, after finishing lower in three of the previous six years.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over MLAB on returns for 2026, with the stronger performance.